相关实验视频
Updated: Jan 16, 2026

08:02
Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
Published on: March 6, 2012
16.9K
多形质母细胞瘤的放射治疗:进化,局限性和分子导向的未来
Castalia Fernández1,2, Raquel Ciérvide3, Ana Díaz4,5
1Department of Radiation Oncology, Hospital Universitario San Francisco de Asís, GenesisCare, 28002 Madrid, Spain.
Biomedicines
|September 27, 2025
概括
多种质母细胞瘤 (GBM) 的放射治疗已经通过先进的技术和向治疗来发展. 尽管有所改善,但复发和耐药性等挑战需要持续的研究,以获得更好的患者结果.
科学领域:
- 神经瘤学神经瘤学
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
- 复发和耐治疗性是GBM管理中的重大挑战.
- 放射治疗 (RT) 是GBM治疗的基石.
研究的目的:
- 审查针对GBM的RT技术的演变.
- 讨论当前的治疗指南和新兴疗法.
- 突出GBM RT的挑战和未来方向.
主要方法:
- 历史和现代技术技术的审查 (IMRT,VMAT).
- 对标准治疗方案 (Stupp协议) 和辅助疗法 (TTFields) 的分析.
- 检查导致复发和放射电阻的因素 (EGFR,PTEN,缺氧,干细胞).
主要成果:
- 斯图普协议与temozolomide (TMZ) 改善了整体存活率 (OS).
- 瘤治疗场 (TTFields) 进一步延长了生存期,特别是在MGMT甲基化GBM中.
- 在被辐射场的2厘米范围内,高复发率仍然存在.
结论:
- 先进的RT技术和辅助疗法改善了GBM的结果.
- 瘤生物学,缺氧和干细胞驱动抵抗和复发.
- 个性化的RT策略,新型药物和先进的成像对于未来的进步至关重要.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K

